NCT02955940 2025-12-17An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibIncyte CorporationPhase 2 Active not recruiting10 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02080260 2022-04-21A Study of Regorafenib in Advanced Pancreatic Cancer PatientsWake Forest University Health SciencesPhase 2 Completed20 enrolled 19 charts